Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.61 |
| ▸ | CCR3 | P51677 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 3/20 | 0.57 |
| ▸ | DRD4 | P21917 | 3/20 | 0.57 |
| ▸ | DRD3 | P35462 | 3/20 | 0.57 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 2/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28532094 | 1.00 | ACHE (0.61) | ACHECCR3SIGMAR1HDAC8DRD2 | |
| Hydrochloric Acid SCHEMBL12539267 | 0.92 | ACHE (0.53) | ACHECCR3SIGMAR1HDAC8DRD2 | |
| SCHEMBL22483707 | 0.90 | KCNH2 (0.56) | ACHEHDAC8DRD2DRD4DRD3 | |
| SCHEMBL28781259 | 0.90 | ALDH1A1 (0.55) | ACHECCR3SIGMAR1HDAC8DRD2 | |
| SCHEMBL2538235 | 0.90 | ACHE (0.53) | ACHECCR3SIGMAR1HDAC8DRD2 | |
| SCHEMBL29031133 | 0.86 | KDM4E (0.64) | ACHESIGMAR1HDAC8BCHEMEN1 | |
| SCHEMBL28546647 | 0.84 | HDAC8 (0.64) | SIGMAR1HDAC8DRD2DRD4CXCR4 | |
| SCHEMBL30442828 | 0.84 | HDAC8 (0.64) | SIGMAR1HDAC8DRD2DRD4CXCR4 | |
| SCHEMBL28538945 | 0.84 | HDAC1 (0.59) | ACHESIGMAR1HDAC8DRD2DRD4 | |
| SCHEMBL6983982 | 0.83 | HDAC8 (0.60) | ACHECCR3SIGMAR1HDAC8DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 628 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117924153-A | Preparation method of key intermediate of donepezil bulk drug | 山东盛安贝新材料有限公司南京分公司 | 2024-04-26 | — | — | CN | claimed |
| CN-115960035-A | Method for controlling impurities in donepezil hydrochloride preparation process | 浙江华海药业股份有限公司 | 2023-04-14 | — | — | CN | claimed |
| CN-115960034-A | Method for refining donepezil condensation compound | 浙江华海药业股份有限公司 | 2023-04-14 | — | — | CN | claimed |
| WO-2022091141-A1 | AN IMPROVED PROCESS OF DONEPEZIL HYDOCHLORIDE | VIHITA CHEM PRIVATE LIMITED (IN) | 2022-05-05 | — | — | WO | claimed |
| CN-113979922-A | Preparation method of N-benzylpiperidine-4-formaldehyde and N-benzylpiperidine-4-methanol | 新发药业有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-111484444-B | Synthesis method of N-benzyl-4-piperidine formaldehyde | 常州大学 | 2021-07-30 | — | — | CN | claimed |
| CN-111484444-A | Synthesis method of N-benzyl-4-piperidine formaldehyde | 常州大学 | 2020-08-04 | — | — | CN | claimed |
| CN-106631989-B | A kind of preparation method of the Doneppezil Hydrochloride in relation to substance E | 威海迪素制药有限公司 | 2019-07-16 | — | — | CN | claimed |
| CN-106631989-A | Preparation method of donepezil hydrochloride related substance E | 威海迪素制药有限公司 | 2017-05-10 | — | — | CN | claimed |
| CN-105693596-A | Preparation method of 1-benzyl-4-piperidine formaldehyde | 上海金树树脂粉末有限公司 | 2016-06-22 | — | — | CN | claimed |
| WO-2007119118-A2 | SYNTHESIS AND PREPARATIONS OF INTERMEDIATES AND POLYMORPHS THEREOF USEFUL FOR THE PREPARATION OF DONEPEZIL HYDROCHLORIDE | MEDICHEM S.A. (US) | 2007-10-25 | — | — | WO | claimed |
| CN-1300112-C | Synthesis method of N-benzyl-4-piperidyl formaldehgde | UNIV ZHEJIANG (CN) | 2007-02-14 | — | — | CN | claimed |
| US-20050261343-A1 | Anthranilamides and their use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-11-24 | — | — | US | claimed |
| CN-1556105-A | Synthesis method of N-benzyl-4-piperidyl formaldehgde | 浙江大学 | 2004-12-22 | — | — | CN | claimed |
| US-20040029880-A1 | Anthranyl amides and their use as medicaments | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-02-12 | — | — | US | claimed |
| EP-0983228-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2002-08-07 | — | — | EP | claimed |
| US-20020065230-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-05-30 | — | — | US | claimed |
| CN-1255119-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2000-05-31 | — | — | CN | claimed |
| EP-0983228-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-08 | — | — | EP | claimed |
| WO-1998050342-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261343-A1 | Anthranilamides and their use as pharmaceutical agents | AADAC, ANTXR2, VEGFA | ACHE 3678/4885CCR3 3247/4885SIGMAR1 3868/4885 |
| US-20020065230-A1 | Protease inhibitors | PRSS1, DNPEP, CTSZ | ACHE 1021/4885CCR3 1110/4885SIGMAR1 4799/4885 |
| US-20040029880-A1 | Anthranyl amides and their use as medicaments | AADAC, ANTXR2, VEGFA | ACHE 3294/4885CCR3 3922/4885SIGMAR1 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.